Niklas Mattsson-Carlgren

Has grant

PI, Associate Professor

Lund University

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Niklas Mattsson-Carlgren is an Associate Professor at Lund University in Sweden. His research focuses on Alzheimer’s disease and neurodegeneration, with recent articles addressing topics such as cognitive testing, plasma biomarker profiles, and genetic risks. He investigates the interplay of amyloid and tau pathology, as well as potential biomarkers for both Alzheimer’s disease and parkinsonian disorders.

Recent Grants

Grant: Close

Motor-ACT: Motor aspects and activities in relation to cognitive decline

Open Date: 2018-01-01

Close Date: 2020-12-31

Grant: Close

Mapping preclinical Alzheimer´s disease

Open Date: 2017-01-01

Close Date: 2019-12-31

Grant: Close

Biomarkers for very early prediction of cognitive decline due to Alzheimer´s disease

Open Date: 2012-07-01

Close Date: 2014-06-30

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (15)

Sebastian Palmqvist

Lund University

SWEDEN

Niklas Mattsson-Carlgren

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests

APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-β

Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers

Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease

Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer’s disease

Plasma biomarker profiles in ageing: decoding neurodegeneration in vivo

Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer’s disease

Disentangling genetic risks for development and progression of Alzheimer’s disease

Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals

Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort study

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes

Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

The emerging era of staging Alzheimer’s disease pathology using plasma biomarkers

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Collaborators (15)

Sebastian Palmqvist

Tobey Betthauser

Sandhitsu Das

Noëlle Warmenhoven

Claudia Cicognola

Oskar Hansson

John Morris

Gunnar Engström

Joana Braga Pereira

Alexa Pichet Binette

Patrik Midlöv

Peter Nilsson

Ruben Smith

Danielle van Westen

Erik Stomrud

Make your next move.